Related Experiment Videos
Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.
American Journal of Respiratory and Critical Care Medicine
|August 1, 1995
Summary
Pulmonary function tests (PFTs) after marrow transplant can predict nonrelapse mortality. Restrictive lung defects or declining total lung capacity (TLC) significantly increase mortality risk, primarily from respiratory failure.
Area of Science:
- Medical research
- Pulmonology
- Hematology
Background:
- Marrow transplantation is a life-saving procedure but carries risks.
- Pulmonary complications are a significant cause of nonrelapse mortality post-transplant.
- Predictive markers for nonrelapse mortality are crucial for patient management.
Purpose of the Study:
- To evaluate if pulmonary function test (PFT) results predict nonrelapse mortality after marrow transplantation.
- To identify specific PFT abnormalities associated with increased mortality risk.
Main Methods:
- Prospective, nonrandomized study of 906 marrow recipients.
- Pulmonary function tests (PFTs) performed between 60 and 120 days post-transplant.
- Statistical analysis using log-rank test and Cox proportional hazards modeling.
Main Results:
- 34% of patients developed restrictive ventilatory defects (TLC < 80%) at 3 months.
- A restrictive defect or a significant decline (≥15%) in total lung capacity (TLC) doubled the risk of nonrelapse mortality.
- Abnormal TLC predicted death from respiratory failure, not chronic graft-versus-host disease (GVHD).
Conclusions:
- PFTs, particularly TLC measurements, are valuable predictors of nonrelapse mortality post-marrow transplant.
- Restrictive lung defects and declining lung volumes identify high-risk patients.
- Findings highlight the importance of monitoring pulmonary function to mitigate mortality risk, mainly due to respiratory failure.